KLRK1 and cancer: It was hypothesized that targeting the p53 pathway in cancer cells could transiently upregulate NKG2D ligands on tumor cells, thus increasing tumor immunogenicity to NK cells, igniting a proinflammatory tumor microenvironment, and ultimately enhancing CD8+ T-cell control of preclinical solid tumors [24].